GlassScriptPhysician profile
Aziza Zaman
NPI 1467422147
$1,448.03
in general payments reported to CMS, 2019-2025
20 companies · $161 in 2025
The $161 reported for 2025 was more than what a typical Pediatrics provider received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $298 · 2020: $70.66 · 2021: $295 · 2022: $231 · 2023: $181 · 2024: $211 · 2025: $161.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $553.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $552.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $216.37 | 2019-2024 | |
| Merck Sharp & Dohme LLC | $192.35 | 2019-2025 | Gardasil 9, Vaxelis, M-M-R II |
| Cranial Technologies, INC | $168.50 | 2024-2025 | Doc Band |
| Glaxosmithkline, LLC. | $135.23 | 2021-2024 | Bexsero, Rotarix |
| Hologic Sales and Service, LLC | $121.77 | 2022-2025 | Aptima |
| Takeda Pharmaceuticals U.S.A., INC. | $90.82 | 2019-2021 | |
| Ironshore Pharmaceuticals INC. | $81.55 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $73.29 | 2021-2022 | |
| Kaleo, INC. | $46.42 | 2022 | |
| Ultragenyx Pharmaceutical INC. | $45.88 | 2021-2023 | |
| Sobi, INC | $44.15 | 2020-2021 | |
| Alexion Pharmaceuticals, INC. | $42.41 | 2019-2022 | |
| Seqirus USA INC | $38.96 | 2022-2023 | Flucelvax Quadrivalent |
| Mayne Pharma Commercial LLC | $29.62 | 2023 | |
| Ars Pharmaceuticals Operations, INC. | $21.53 | 2025 | Neffy |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi Pasteur INC. | $21.24 | 2024 | |
| Alk-Abello, INC | $21.11 | 2025 | Neffy |
| Neos Therapeutics, LP | $20.00 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $19.06 | 2021 | |
| Dermira, INC. | $17.77 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aziza Zaman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.